Edition:
India

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

0.95USD
1:30am IST
Change (% chg)

$-0.00 (-0.05%)
Prev Close
$0.95
Open
$0.96
Day's High
$1.00
Day's Low
$0.93
Volume
161,141
Avg. Vol
143,690
52-wk High
$7.26
52-wk Low
$0.91

Latest Key Developments (Source: Significant Developments)

Bellicum Pharmaceuticals Announces Proposed $53 Mln Public Offering Of Preferred Stock And Warrants With Concurrent Private Placement
Friday, 16 Aug 2019 

Aug 15 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS ANNOUNCES PROPOSED $53.0 MILLION PUBLIC OFFERING OF PREFERRED STOCK AND WARRANTS WITH CONCURRENT PRIVATE PLACEMENT.BELLICUM PHARMACEUTICALS - TO SELL SHARES OF SERIES 1 PREFERRED STOCK & WARRANTS TO BUY COMMON STOCK IN PUBLIC OFFERING FOR PROCEEDS OF ABOUT $53 MILLION.BELLICUM PHARMACEUTICALS INC - EXPECTS CONCURRENT PRIVATE PLACEMENT TO BE FOR AGGREGATE GROSS PROCEEDS OF $70.0 MILLION.  Full Article

Bellicum Pharmaceuticals Inc Files For Mixed Shelf Of Upto $400 Million
Wednesday, 24 Jul 2019 

July 23 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $400 MILLION - SEC FILING.  Full Article

Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results And Provides Operational Update
Tuesday, 7 May 2019 

May 7 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE.BELLICUM PHARMACEUTICALS INC - BELLICUM REPORTED CASH, RESTRICTED CASH AND INVESTMENTS TOTALING $78.1 MILLION AS OF MARCH 31, 2019.BELLICUM PHARMACEUTICALS INC - EXPECTS THAT CURRENT CASH RESOURCES WILL BE SUFFICIENT TO MEET OPERATING REQUIREMENTS THROUGH END OF 2019.BELLICUM PHARMACEUTICALS INC - QTRLY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON SHAREHOLDERS, BASIC AND DILUTED $0.55.  Full Article

Bellicum Pharma Qtrly Loss Per Share $0.55
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.QTRLY LOSS PER SHARE $0.55.Q3 EARNINGS PER SHARE VIEW $-0.58 -- THOMSON REUTERS I/B/E/S.  Full Article

Bellicum Pharmaceuticals Reports Q1 Loss Per Share Of $0.68
Wednesday, 9 May 2018 

May 8 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.QTRLY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON SHAREHOLDERS $0.68.Q1 EARNINGS PER SHARE VIEW $-0.69 -- THOMSON REUTERS I/B/E/S.QTRLY GRANT REVENUE $154,000 VERSUS $128,000.Q1 REVENUE VIEW $32860.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Bellicum Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Tuesday, 17 Apr 2018 

April 16 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 7.00 MILLION COMMON SHARES.  Full Article

Bellicum Pharmaceuticals Reports Qtrly Loss Per Share $0.66
Wednesday, 14 Mar 2018 

March 13 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS PROVIDES OPERATIONAL UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017.‍REMAINS ON TRACK TO FILE EUROPEAN MARKETING AUTHORIZATION APPLICATIONS FOR BPX-501 AND RIMIDUCID IN 2019​.QTRLY LOSS PER SHARE $0.66‍​.Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.  Full Article

Bellicum Announces Interim Results Showing Low Rates Of Cancer Recurrence In Pediatric AML Patients Treated With BPX-501
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM ANNOUNCES INTERIM RESULTS SHOWING LOW RATES OF CANCER RECURRENCE IN PEDIATRIC AML PATIENTS TREATED WITH BPX-501.BELLICUM PHARMA - WORKING WITH INVESTIGATORS & U.S. FDA TO DEVELOP PROTOCOL FOR POTENTIAL U.S. REGISTRATION STUDY IN PEDIATRIC PATIENTS.BELLICUM PHARMA - EXPECTS TO INITIATE POTENTIAL U.S. REGISTRATION STUDY IN PEDIATRIC PATIENTS BY END OF 2018.BELLICUM PHARMA - FROM BP-004 STUDY, CO REPORTED HIGH RATES OF DISEASE-FREE SURVIVAL & OVERALL SURVIVAL IN PEDIATRIC PATIENTS WITH PID.  Full Article

Bellicum Pharma Says Effective Feb 20, Board Approved Increase In Size Of Board To 8 Members
Saturday, 24 Feb 2018 

Feb 23 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMA SAYS EFFECTIVE FEB 20, BOARD APPROVED INCREASE IN SIZE OF BOARD TO 8 MEMBERS - SEC FILING.  Full Article

Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies
Friday, 23 Feb 2018 

Feb 23 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM ANNOUNCES UPDATE ON CLINICAL HOLD OF U.S. BPX-501 STUDIES.BELLICUM - RECEIVED NOTIFICATION FROM FDA OUTLINING CRITERIA REQUIRED FOR LIFTING CLINICAL HOLD ON U.S. STUDIES OF BPX-501.BELLICUM PHARMACEUTICALS INC - CLINICAL HOLD DOES NOT AFFECT COMPANY'S BP-004 REGISTRATION TRIAL IN EUROPE.BELLICUM - PLANS TO IMPLEMENT REVISIONS TO U.S. STUDY PROTOCOLS, ADDITION OF MORE COMPREHENSIVE MONITORING, MANAGEMENT OF NEUROTOXICITY FOR BPX-501.  Full Article